An Overview of Hospital-Acquired MRSA (HA-MRSA) in Healthcare Settings

Aka Healthcare-Acquired MRSA

Table of Contents
View All
Table of Contents

Hospital-acquired methicillin-resistant Staphylococcus aureus, also known as healthcare-acquired MRSA or HA-MRSA, is a potentially deadly strain of staph bacteria. It occurs in people who've been in a hospital or other healthcare setting, like a dialysis center or nursing home. This superbug, resistant to many antibiotics, has long been a public health concern, with more than 3,700 hospitals in the United States reporting one or more incidents of HA-MRSA in 2022.

Despite inordinately high rates of infection in the latter part of the 20th century, there has been a slow decline in MRSA diagnoses since then due to increased awareness and a rigorous adherence to universal precautions in healthcare settings.

This article will explain the symptoms and causes of HA-MRSA. It will also discuss which risks hospitals and other healthcare settings pose and what the infection rates are. You'll learn how HA-MRSA is diagnosed and treated and what can be done to prevent it.

Microbiologist holding a culture plate of an MRSA
Rodolfo Parulan Jr / Getty Images

Symptoms of Hospital-Acquired MRSA

MRSA infections can appear as a small red bump, pimple, boil, or abscess. The affected area may be warm, swollen, or tender to the touch. Fever may also accompany this. Less commonly, an MRSA infection can cause chest pains, chills, fatigue, headache, or rash.

Most MRSA infections are mild, but some can spread and become systemic (involving the whole body). This can lead to potentially life-threatening infections of bones, joints, heart valves, lungs, and the bloodstream.

Some of the possible complications of MRSA infection include:

HA-MRSA infections are generally defined as those that develop within 48 hours of discharge from a hospital, clinic, or healthcare facility.

Causes of Hospital-Acquired MRSA

There are many different variations of staph bacteria. Most are relatively harmless and usually only cause minor skin problems in healthy people.

However, with the widespread, inappropriate use of antibiotics around the world, mutated strains of Staphylococcus aureus have begun to emerge, many of which are resistant to a broad spectrum of antibiotic drugs.

Anyone can get MRSA. The risk increases in places where people regularly gather and either have skin-to-skin contact or exposure to shared equipment or supplies. The risk is further increased if there is broken or non-intact skin.

How Resistance Develops

Staphylococcus aureus, like all bacteria, is prone to mutations. Most of these mutations are harmless and result in weak bacteria that are unable to survive. On the odd occasion, however, a mutation may result in a drug-resistant strain.

Even if this occurs, it won't usually undermine the effectiveness of an antibiotic since it won't be the predominant strain. This can change, however, if antibiotics are overprescribed or used improperly.

For example, if you are on a seven-day course of antibiotics and stop prematurely before an infection is fully resolved, the predominant strain—the type most sensitive to antibiotics—will be neutralized but not the resistant one. The more that this pattern is repeated, the larger the resistance population will become, filling the gap left by the predominant bacteria and eventually becoming dominant itself.

As a resistant bacterium is passed from person to person, it can pick up additional mutations from those who have been inappropriately treated with other types of antibiotics. Over time, the antibiotic-resistant bacterium may evolve into a fully multi-drug-resistant superbug.

How MRSA Infections Are Established

Staphylococcus aureus is uniquely suited to survive. Its external protein shell (capsid) is dense enough to live outside of the human body for days or weeks and sticky enough to adhere to different surfaces, including the skin.

Staphylococcus aureus also secretes a variety of proteins that either inhibit or kill white blood cells that the body uses to neutralize disease-causing microorganisms. By doing so, the bacteria can evade the front-line immune assault and quickly establish an infection.

In hospital settings, Staphylococcus aureus can form a slimy material, called a biofilm, that serves as a protective barrier against even the more potent antimicrobial agents.

In addition, many of the symptoms of MRSA occur as a result of tissue destruction by enzymes secreted by the bacterium. Among other things, Staphylococcus aureus secretes a type of toxin, classified as a superantigen, that allows it to penetrate the skin more readily and enter the bloodstream, increasing the risk of sepsis and septic shock.

Risks in Hospitals and Other Healthcare Settings

Hospitals and healthcare facilities pose the greatest risk of person-to-person transmission of superbugs like MRSA. HA-MRSA infections frequently occur in these settings for several reasons:

  • These are sites where a large stream of people come and go.
  • People regularly undergo invasive procedures, have open wounds, and/or have significantly weakened immune systems due to illness.
  • Failure to wash hands and surfaces frequently can foster the spread of MRSA in settings like these.

Many hospital patients are carriers of HA-MRSA even though they do not have symptoms. Transmission can also occur when a healthcare worker touches one patient and then another without washing their hands or using barrier protection (like disposable latex gloves). Other sources of transmission include catheters, breathing tubes, bed linens, and bed rails.

Infection Rates of Hospital-Acquired MRSA

According to a 2019 report issued by the Centers for Disease Control and Prevention (CDC), Staphylococcus aureus caused well over 110,000 bloodstream infections in the United States in 2017, resulting in nearly 20,000 deaths. As distressing as these numbers sound, they represent a steady decline from the 1990s when MRSA infections appeared out of control.

Due to improved surveillance and infection control practices, the rate of MRSA diagnoses in the United States is declining and the decrease is significant. There has been an 10% decrease in infection rates from 2015 to 2022.

How Hospital-Acquired MRSA Is Diagnosed

MRSA is diagnosed by checking a tissue sample or nasal secretions for signs of drug-resistant bacteria. Traditional tests are cultured in a lab to see if the suspected bacteria are present and can usually return results in 48 hours. Newer DNA tests can return results in a matter of hours.

Depending on your symptoms, your healthcare provider may recommend additional tests, such as blood culture, drainage from the infection, skin culture, sputum culture, or urine culture, to diagnose complications of HA-MRSA.

Hospital-Acquired MRSA Treatment

HA-MRSA is resistant to beta-lactam antibiotics. These include penicillin and its derivatives, cephalosporins, monobactams, carbapenems, and carbacephems. This means that many of the more commonly prescribed antibiotics, like methicillin, amoxicillin, penicillin, and oxacillin, will have little to no effect on the bacteria.

Fortunately, HA-MRSA can still be treated with other types of antibiotics, including clindamycin, linezolid, tetracycline, trimethoprim-sulfamethoxazole, or vancomycin. The choice will depend largely on the MRSA strain prevalent in the region and the severity of the illness.

The standard duration of antibiotic therapy for an HA-MRSA infection is between seven and 10 days. Serious infections may require longer treatment and intravenous (IV) drug delivery.

In some cases, however, antibiotics may not be needed. For example, your healthcare provider may opt to drain a superficial abscess rather than treat the infection with antibiotics. This antibiotic-sparing approach recognizes that antibiotics are not necessarily needed if an infection is mild and your immune system is strong.

Serious infections requiring hospitalization may also involve therapies and procedures to treat MRSA complications. Examples include kidney dialysis in cases of acute kidney failure and oxygen therapy in cases of severe pneumonia.

How to Prevent Hospital-Acquired MRSA

To prevent getting or spreading MRSA, there are some simple precautions you should take during and after your stay in a hospital or other healthcare facility:

  • Wash your hands often: Wash thoroughly between the fingers and under the nails with soap and warm water, or use an alcohol-based hand sanitizer.
  • Avoid contact with other people's wounds: If you accidentally touch a wound, wash your hands immediately and avoid touching surfaces, yourself, or others until you do.
  • Do not share personal care items: This includes towels, razors, skincare products, washcloths, and clothing.
  • Avoid walking with bare feet: Even if you need to go to the bathroom in the middle of the night, wear slippers with non-absorbent soles.
  • Keep your wounds covered: Once home, change your bandages regularly (per your healthcare provider's instructions) using fresh bandages and cleaning the skin thoroughly with the appropriate antimicrobial agent, like Betadine solution (povidone-iodine).
  • Dispose of bandages and tape promptly: Do not wait for others to clear them for you. The fewer hands that are involved, the better.

Summary

Hospital-acquired methicillin-resistant Staphylococcus aureus is an infection that you can get in hospitals or other healthcare settings. Most HA-MRSA infections are mild, but some can cause severe symptoms, complications, and potentially death.

The bacterium that causes these infections can live on surfaces outside the human body for days or weeks. Mutations in the bacterium can create antibiotic resistance, making the treatment of this infection challenging. Hospitals and other healthcare settings are common places of transmission, but infection rates have been declining.

Laboratory tests are needed to diagnose HA-MRSA, and alternative antibiotics are usually available for treatment. Wash your hands often and take other preventative measures to prevent getting or spreading HA-MRSA after visiting a hospital or other healthcare facility. See a healthcare provider if you develop symptoms to get proper treatment.

13 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. Centers for Disease Control and Prevention. Antimicrobial Resistance & Patient Safety Portal: Methicillin-resistant Staphylococcus aureus.

  2. Hassoun A, Linden PK, Friedman B. Incidence, prevalence, and management of MRSA bacteremia across patient populations—a review of recent developments in MRSA management and treatmentCrit Care. 2017:21(1):211. doi:10.1186/s13054-017-1801-3

  3. Garoy EY, Gebreab YB, Achila OO, et al. Methicillin-resistant (MRSA): prevalence and antimicrobial sensitivity pattern among patients-a multicenter study in Asmara, Eritrea. Can J Infect Dis Med Microbiol. 2019:8321834. doi:10.1155/2019/8321834

  4. Fukunaga BT, Sumida WK, Taira DA, Davis JW, Seto TB. Hospital-acquired methicillin-resistant Staphylococcus aureus bacteremia related to Medicare antibiotic prescriptions: A state-level analysisHawaii J Med Public Health. 2016;75(10):303-9.

  5. Green BN, Johnson CD, Egan JT, Rosenthal M, Griffith EA, Evans MW. Methicillin-resistant Staphylococcus aureus: an overview for manual therapists. J Chiropr Med. 2012;11(1):64-76. doi:10.1016/j.jcm.2011.12.001

  6. Dearborn AD, Wall EA, Kizziah JL, et al. Competing scaffolding proteins determine capsid size during mobilization of Staphylococcus aureus pathogenicity islandsElife. 2017;6:e30822. doi:10.7554/eLife.30822

  7. Thammavongsa V, Kim HK, Missiakas D, Schneewind O. Staphylococcal manipulation of host immune responses. Nat Rev Microbiol. 2015;13(9):529-43.  doi:10.1038/nrmicro3521

  8. Manandhar S, Singh A, Varma A, Pandey S, Shrivastava N. Biofilm producing clinical Staphylococcus aureus isolates augmented prevalence of antibiotic-resistant cases in tertiary care Hospitals of NepalFront Microbiol. 2018;9:2749. doi:10.3389/fmicb.2018.02749

  9. Krakauer T, Pradhan K, Stiles BG. Staphylococcal superantigens spark host-mediated danger signals. Front Immunol. 2016;7:23. doi:10.3389/fimmu.2016.00023

  10. Uhlemann AC, Otto M, Lowy FD, DeLeo FR. Evolution of community- and healthcare-associated methicillin-resistant Staphylococcus aureusInfect Genet Evol. 2014;21:563-74. doi:10.1016/j.meegid.2013.04.030

  11. Centers for Disease Control and Prevention. Methicillin-resistant Staphylococcus aureus (MRSA): for patients.

  12. Choo EJ, Chambers HF. Treatment of methicillin-resistant Staphylococcus aureus bacteremiaInfect Chemother. 2016;48(4):267-73. doi:10.3947/ic.2016.48.4.267

  13. Ray SM. Preventing methicillin-resistant Staphylococcus aureus (MRSA) disease in urban US hospitals—now for the hard part: more evidence pointing to the community as the source of MRSA acquisition. J Infect Dis. 2017;11(215):1631-3. doi:10.1093/infdis/jix109

Additional Reading

By Ingrid Koo, PhD
 Ingrid Koo, PhD, is a medical and science writer who specializes in clinical trial reporting